GlassScriptPhysician profile
Abdul Jalil
NPI 1568621365
$2,274.65
in general payments reported to CMS, 2019-2025
30 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.41 · 2021: $635 · 2022: $737 · 2023: $462 · 2024: $204 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.12 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.63 | 2021-2025 | |
| Biogen, INC. | $259.19 | 2021-2023 | Tysabri, Vumerity |
| Ucb, INC. | $256.47 | 2021-2025 | Briviact |
| Emd Serono, INC. | $231.31 | 2021-2024 | |
| Amgen INC. | $106.03 | 2022 | |
| Pfizer INC. | $105.12 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $82.44 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.26 | 2022 | |
| Lilly USA, LLC | $55.75 | 2021-2024 | Reyvow, Emgality |
| Biohaven Pharmaceuticals, INC. | $48.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.02 | 2021 | |
| Boston Scientific Corporation | $45.94 | 2021 | |
| Celgene Corporation | $44.41 | 2023-2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $39.86 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $38.32 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $32.20 | 2023 | Infinity |
| Mdd US Operations, LLC | $32.20 | 2021-2022 | |
| Sk Life Science, INC. | $30.32 | 2021-2022 | |
| Ge Healthcare | $26.67 | 2022 | |
| Axsome Therapeutics, INC. | $25.35 | 2025 | Symbravo |
| Microtransponder, INC. | $22.90 | 2025 | |
| Avanir Pharmaceuticals, INC. | $22.68 | 2022 | |
| Kyowa Kirin, INC. | $19.55 | 2021 | |
| Allergan, INC. | $19.41 | 2020 | |
| Impel Pharmaceuticals INC. | $19.11 | 2022 | |
| Genzyme Corporation | $18.49 | 2022 | |
| Sumitomo Pharma America, INC. | $18.47 | 2023 | Aptiom |
| Amneal Pharmaceuticals LLC | $16.78 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.61 | 2021 | |
| Avion Pharmaceuticals | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.